Article
Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2
medRxiv: the preprint server for health sciences · 2020 · Raymond T. Suhandynata, author Melissa A. Hoffman, author Deli Huang, author Jenny T. Tran, author Michael J. Kelner, author Sharon L. Reed, author Ronald W. McLawhon, author James E. Voss, author David Nemazee, author Robert L. Fitzgerald, author
Key facts
| Title | Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2 |
|---|---|
| First author | Raymond T. Suhandynata, author Melissa A. Hoffman, author Deli Huang, author Jenny T. Tran, author Michael J. Kelner, author Sharon L. Reed, author Ronald W. McLawhon, author James E. Voss, author David Nemazee, author Robert L. Fitzgerald, author |
| Journal | medRxiv : the preprint server for health sciences |
| Published | Jul 21, 2020 |
| DOI | 10.1101/2020.07.10.20150946 |
| Devices mentioned | BK230839, BK230840, K000042, K000155, K000270, K000534, K000576, K001014, K001015, K001468, K001846, K001906 and 223 more |
| Product codes mentioned | CDD, CDP, CDS, CDX, CDZ, CEC, CEM, CEP, CEW, CFL, CFP, CFT and 101 more |
At a glance
- 100–999 FDA submissions mentioned
- 100–999 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1